Astera Labs, Inc. $ALAB Shares Bought by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC lifted its stake in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 142.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,366 shares of the company's stock after acquiring an additional 6,677 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in Astera Labs were worth $1,028,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in ALAB. Alliancebernstein L.P. lifted its stake in shares of Astera Labs by 114.2% in the 1st quarter. Alliancebernstein L.P. now owns 8,401,019 shares of the company's stock worth $501,289,000 after acquiring an additional 4,478,741 shares during the period. Atreides Management LP lifted its stake in shares of Astera Labs by 153.3% in the 1st quarter. Atreides Management LP now owns 4,652,264 shares of the company's stock worth $277,601,000 after acquiring an additional 2,815,614 shares during the period. FengHe Fund Management Pte. Ltd. acquired a new stake in shares of Astera Labs in the 2nd quarter worth approximately $106,772,000. Bank of Nova Scotia lifted its stake in shares of Astera Labs by 3,742.2% in the 1st quarter. Bank of Nova Scotia now owns 964,400 shares of the company's stock worth $57,546,000 after acquiring an additional 939,300 shares during the period. Finally, Jump Financial LLC acquired a new stake in shares of Astera Labs in the 1st quarter worth approximately $32,998,000. 60.47% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Astera Labs

In related news, Director Jack R. Lazar sold 22,500 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $178.42, for a total transaction of $4,014,450.00. Following the transaction, the director directly owned 97,351 shares of the company's stock, valued at approximately $17,369,365.42. The trade was a 18.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, General Counsel Philip Mazzara sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $192.16, for a total transaction of $1,921,600.00. Following the transaction, the general counsel directly owned 151,573 shares in the company, valued at $29,126,267.68. The trade was a 6.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,092,997 shares of company stock valued at $192,231,120 over the last three months. 12.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ALAB. Evercore ISI upped their price target on shares of Astera Labs from $104.00 to $215.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 6th. Zacks Research downgraded shares of Astera Labs from a "strong-buy" rating to a "hold" rating in a report on Monday, October 6th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Astera Labs from $160.00 to $200.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Wall Street Zen upgraded shares of Astera Labs from a "hold" rating to a "buy" rating in a report on Saturday. Finally, Northland Securities downgraded shares of Astera Labs from an "outperform" rating to a "market perform" rating and set a $120.00 target price on the stock. in a report on Tuesday, July 22nd. Fifteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $162.06.

Astera Labs Price Performance

ALAB stock opened at $159.80 on Monday. Astera Labs, Inc. has a 52-week low of $47.13 and a 52-week high of $262.90. The company's 50 day simple moving average is $199.68 and its 200-day simple moving average is $128.80. The firm has a market capitalization of $26.56 billion, a P/E ratio of 285.36, a P/E/G ratio of 3.98 and a beta of 1.43.

Astera Labs (NASDAQ:ALAB - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.33 by $0.11. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The business had revenue of $191.93 million for the quarter, compared to analyst estimates of $172.46 million. During the same quarter in the previous year, the business earned $0.13 earnings per share. The firm's revenue was up 149.5% compared to the same quarter last year. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. Sell-side analysts predict that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.